Crown Laboratories, Inc., Thursday announced the commencement of a cash tender offer to acquire Revance Therapeutics, Inc., (RVNC) at a price of $3.10 per share.
The Revance board concluded that the offer is in the best interest of its shareholders. The company also said it has considered factors such as the changing dynamics of the aesthetic injectable market, and the potential risks related to its outstanding debt obligations.
The offer is set to expire at one minute after 11:59 p.m., ET on January 13, 2025, the privately held skincare company added.
Currently, Revance's stock is moving up 1.31 percent, to $3.08 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.